%0 Journal Article
%T Volume doubling time of lung adenocarcinomas considering epidermal growth factor receptor mutation status of exon 19 and 21: three-dimensional volumetric evaluation
%A Bojiang Chen
%A Jing Jin
%A Longchao Zhao
%A Ping Zhou
%A Rui Zhang
%A Weimin Li
%A Yongzhao Zhou
%J SCIE-indexed Journal
%D 2017
%R 10.21037/jtd.2017.10.58
%X Epidermal growth factor receptor (EGFR), a member of the ErbB receptor tyrosine kinase family, harbors tumor associated mutations that have been documented in exon 18 through 21, mainly involving exon 19 and exon 21. Previous studies have revealed that EGFR mutation status is closely related to the manifestation and prognosis of lung adenocarcinomas (1-3). In advanced non-small cell lung cancer (NSCLC) patients, the mutation in exon 19 could provide superior objective response rate (ORR), one-year progression-free survival (PFS), and two-year overall survival (OS) after EGFR-tyrosine kinase inhibitors (EGFR-TKIs) treatment when compared with mutation in exon 21 (4-6). Nevertheless, patients with mutation in exon 19 may have few choices available during gradual progression and sometimes obtain survival benefit from chemotherapy during dramatic progression, while patients with dramatic or gradual progression could both benefit from previous TKI continuation in exon 21 mutation patients (7). Therefore, the EGFR mutation subtypes should be considered when making treatment decision for EGFR mutation-positive NSCLC patients
%U http://jtd.amegroups.com/article/view/16982/html